Literature DB >> 21212175

3-hydroxykynurenine suppresses CD4+ T-cell proliferation, induces T-regulatory-cell development, and prolongs corneal allograft survival.

Sarah S Zaher1, Conrad Germain, Hongmei Fu, Daniel F P Larkin, Andrew J T George.   

Abstract

PURPOSE: IDO (indoleamine 2,3-dioxygenase) modulates the immune response by depletion of the essential amino acid tryptophan, and IDO overexpression has been shown to prolong corneal allograft survival. This study was conducted to examine the effect of kynurenines, the products of tryptophan breakdown and known to act directly on T lymphocytes, on corneal graft survival.
METHODS: The effects of kynurenines on T-cell proliferation and death, T-regulatory-cell development, and dendritic cell function, phenotype, and viability were analyzed in vitro. The effect of topical and systemic administration of 3-hydroxykynurenine (3HK) on orthotopic murine corneal allograft survival was examined.
RESULTS: T-lymphocyte proliferation was inhibited by two of the four different kynurenines: 3HK and 3-hydroxyanthranilic acid (3HAA). This effect was accompanied by significant T-cell death. Neither 3HK nor 3HAA altered dendritic cell function, nor did they induce apoptosis or pathogenicity to corneal endothelial cells. Administration of systemic and topical 3HK to mice receiving a fully mismatched corneal graft resulted in significant prolongation of graft survival (median survival of control grafts, 12 days; of treated, 19 and 15 days, respectively; P < 0.0003). While systemic administration of 3HK was associated with a significant depletion of CD4(+) T, CD8(+) T, and B lymphocytes in peripheral blood, no depletion was found after topical administration.
CONCLUSIONS: The production of kynurenines, in particular 3HK and 3HAA, may be one mechanism (in addition to tryptophan depletion) by which IDO prolongs graft survival. These molecules have potential as specific agents for preventing allograft rejection in patients at high rejection risk.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21212175      PMCID: PMC3088555          DOI: 10.1167/iovs.10-5793

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  48 in total

1.  Human lymphocyte subpopulations. Effect of corticosteroids.

Authors:  D T Yu; P J Clements; H E Paulus; J B Peter; J Levy; E V Barnett
Journal:  J Clin Invest       Date:  1974-02       Impact factor: 14.808

2.  Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells.

Authors:  Francesca Fallarino; Carmine Vacca; Ciriana Orabona; Maria L Belladonna; Roberta Bianchi; Brendan Marshall; Derin B Keskin; Andrew L Mellor; Maria C Fioretti; Ursula Grohmann; Paolo Puccetti
Journal:  Int Immunol       Date:  2002-01       Impact factor: 4.823

3.  3-Hydroxyanthranilic acid, an L-tryptophan metabolite, induces apoptosis in monocyte-derived cells stimulated by interferon-gamma.

Authors:  T Morita; K Saito; M Takemura; N Maekawa; S Fujigaki; H Fujii; H Wada; S Takeuchi; A Noma; M Seishima
Journal:  Ann Clin Biochem       Date:  2001-05       Impact factor: 2.057

4.  Regulation of myeloperoxidase-specific T cell responses during disease remission in antineutrophil cytoplasmic antibody-associated vasculitis: the role of Treg cells and tryptophan degradation.

Authors:  Konstantia-Maria Chavele; Deepa Shukla; Tracey Keteepe-Arachi; Judith Anna Seidel; Dietmar Fuchs; Charles D Pusey; Alan D Salama
Journal:  Arthritis Rheum       Date:  2010-05

5.  The effect of corticosteroid and cyclosporin A on murine corneal allograft rejection.

Authors:  E P Zhang; F Schulte; S Bulfone-Paus; F Hoffmann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2000-06       Impact factor: 3.117

6.  Mechanisms of corneal graft rejection: the sixth annual Thygeson Lecture, presented at the Ocular Microbiology and Immunology Group meeting, October 21, 2000.

Authors:  J Y Niederkorn
Journal:  Cornea       Date:  2001-10       Impact factor: 2.651

7.  Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis.

Authors:  Kenichi Sakurai; Jian-Ping Zou; Jolynne R Tschetter; Jerrold M Ward; Gene M Shearer
Journal:  J Neuroimmunol       Date:  2002-08       Impact factor: 3.478

8.  Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection.

Authors:  Maria Friberg; Ronald Jennings; Marwan Alsarraj; Sophie Dessureault; Alan Cantor; Martine Extermann; Andrew L Mellor; David H Munn; Scott J Antonia
Journal:  Int J Cancer       Date:  2002-09-10       Impact factor: 7.396

9.  Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites.

Authors:  Peter Terness; Thomas M Bauer; Lars Röse; Christoph Dufter; Andrea Watzlik; Helmut Simon; Gerhard Opelz
Journal:  J Exp Med       Date:  2002-08-19       Impact factor: 14.307

10.  Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase.

Authors:  Guido Frumento; Rita Rotondo; Michela Tonetti; Gianluca Damonte; Umberto Benatti; Giovanni Battista Ferrara
Journal:  J Exp Med       Date:  2002-08-19       Impact factor: 14.307

View more
  27 in total

Review 1.  Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer.

Authors:  Srikanth Santhanam; David M Alvarado; Matthew A Ciorba
Journal:  Transl Res       Date:  2015-08-03       Impact factor: 7.012

Review 2.  The cellular metabolic landscape in the tumor milieu regulates the activity of myeloid infiltrates.

Authors:  Eslam Mohamed; Amir A Al-Khami; Paulo C Rodriguez
Journal:  Cell Mol Immunol       Date:  2018-03-22       Impact factor: 11.530

Review 3.  Targeting TDO in cancer immunotherapy.

Authors:  Cheng-Peng Yu; Yun-Lei Song; Zheng-Ming Zhu; Bo Huang; Ying-Qun Xiao; Da-Ya Luo
Journal:  Med Oncol       Date:  2017-03-29       Impact factor: 3.064

Review 4.  Different partners, opposite outcomes: a new perspective of the immunobiology of indoleamine 2,3-dioxygenase.

Authors:  Ciriana Orabona; Maria Teresa Pallotta; Ursula Grohmann
Journal:  Mol Med       Date:  2012-07-18       Impact factor: 6.354

5.  Elevated serum levels of kynurenine pathway metabolites in patients with Behçet disease.

Authors:  Duygu Eryavuz Onmaz; Dilek Tezcan; Sedat Abusoglu; Abdullah Sivrikaya; Menekse Kuzu; Fatma Humeyra Yerlikaya; Sema Yilmaz; Ali Unlu
Journal:  Amino Acids       Date:  2022-05-23       Impact factor: 3.520

6.  Activation of NAD(P)H oxidase by tryptophan-derived 3-hydroxykynurenine accelerates endothelial apoptosis and dysfunction in vivo.

Authors:  Qiongxin Wang; Miao Zhang; Ye Ding; Qilong Wang; Wencheng Zhang; Ping Song; Ming-Hui Zou
Journal:  Circ Res       Date:  2013-11-26       Impact factor: 17.367

Review 7.  Indoleamine 2,3 dioxygenase and metabolic control of immune responses.

Authors:  David H Munn; Andrew L Mellor
Journal:  Trends Immunol       Date:  2012-10-25       Impact factor: 16.687

8.  Suppression of the allogeneic response by the anti-allergy drug N-(3,4-dimethoxycinnamonyl) anthranilic acid results from T-cell cycle arrest.

Authors:  Sarah S Zaher; David Coe; Jian-Guo Chai; Daniel F P Larkin; Andrew J T George
Journal:  Immunology       Date:  2013-02       Impact factor: 7.397

Review 9.  Tryptophan-kynurenine pathway is dysregulated in inflammation, and immune activation.

Authors:  Qiongxin Wang; Danxia Liu; Ping Song; Ming-Hui Zou
Journal:  Front Biosci (Landmark Ed)       Date:  2015-06-01

10.  Kynurenine/Tryptophan Ratio as a Potential Blood-Based Biomarker in Non-Small Cell Lung Cancer.

Authors:  Martina Mandarano; Elena Orecchini; Guido Bellezza; Jacopo Vannucci; Vienna Ludovini; Sara Baglivo; Francesca Romana Tofanetti; Rita Chiari; Elisabetta Loreti; Francesco Puma; Angelo Sidoni; Maria Laura Belladonna
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.